Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27881263 | 0.94 | HTR2C (0.55) | HTR2CSLC18A3SIGMAR1QDPRTPSAB1 | |
| SCHEMBL27511207 | 0.90 | DRD2 (0.48) | HTR2CSLC18A3SIGMAR1MPO | |
| SCHEMBL3176710 | 0.87 | PNMT (0.47) | TPSAB1PNMT | |
| Hydrochloric Acid SCHEMBL13570531 | 0.85 | PNMT (0.45) | HTR2CTPSAB1PNMT | |
| SCHEMBL25359641 | 0.84 | PRMT6 (0.44) | TPSAB1PNMT | |
| SCHEMBL30531117 | 0.84 | PRMT6 (0.44) | TPSAB1PNMT | |
| SCHEMBL16368536 | 0.84 | HDAC4 (0.47) | TPSAB1PNMT | |
| SCHEMBL4518387 | 0.83 | HTR2C (0.62) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| SCHEMBL7624146 | 0.83 | HTR2C (0.57) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| SCHEMBL22567480 | 0.83 | HTR2C (0.57) | HTR2CSLC18A3SIGMAR1QDPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104926801-B | Substituted azetidine analog derivative, the pharmaceutical composition containing it and its application in antitumor | 浙江大学 | 2019-06-04 | — | — | CN | claimed |
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2020-11-12 | — | — | US | disclosed |
| EP-2693883-B1 | SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2018-12-26 | — | — | EP | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170080001-A1 | SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170080001-A1 | SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| CN-1740169-A | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| CN-1230431-C | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2005-12-07 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| CN-1439003-A | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CALCOCO2, MDN1, MBNL1 | HTR2C 4716/4885SLC18A3 4334/4885SIGMAR1 4436/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | HTR2C 267/4885SLC18A3 693/4885SIGMAR1 2651/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | HTR2C 267/4885SLC18A3 693/4885SIGMAR1 2651/4885 |
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | STIM1, STAMBP, ILK | HTR2C 4749/4885SLC18A3 3980/4885SIGMAR1 3011/4885 |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | HTR2C 4716/4885SLC18A3 4334/4885SIGMAR1 4436/4885 |
| US-20170080001-A1 | SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | STIM1, STAMBP, ILK | HTR2C 4749/4885SLC18A3 3980/4885SIGMAR1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.